PepGen Secures FDA's Orphan Drug, Rare Pediatric Disease Designations For PGN-EDO51

(RTTNews) - Wednesday, PepGen Inc. (PEPG) announced that PGN-EDO51, a potential therapeutic for Duchenne muscular dystrophy or DMD patients, has received orphan drug and rare pediatric disease designations from the FDA.

The company said that PGN-EDO51 is anticipated to be beneficial for patients with mutations suitable for the exon 51 skipping approach.

PepGen is presently assessing PGN-EDO51 in the CONNECT 1 Phase 2 trial and intends to commence patient enrollment in the CONNECT 2 Phase 2 trial later this year.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.